Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exscientia Ltd ADR
(NQ:
EXAI
)
6.000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exscientia Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Exscientia plc (EXAI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
February 07, 2024
From
Exscientia plc
Via
Business Wire
Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
January 02, 2024
From
Exscientia
Via
Business Wire
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
December 21, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
December 05, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Exscientia plc
Via
Business Wire
Unlocking AI investment opportunities in healthcare
November 16, 2023
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Exscientia Business Update for Third Quarter 2023
November 09, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
November 02, 2023
From
Exscientia plc
Via
Business Wire
Parker Moss to Join Exscientia as EVP, Corporate Development
October 17, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
October 16, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Details Pipeline Prioritisation Strategy
October 03, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
September 20, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Present at Upcoming Investor Conferences in September
August 31, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Business Update for Second Quarter and First Half of 2023
August 10, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023
From
Exscientia
Via
Business Wire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
August 01, 2023
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
MarketBeat Week in Review – 7/24 - 7/28
July 29, 2023
Investors continue to look for stocks to buy as inflation cools. As you prepare for another busy week, here are some of our top stories from this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
July 28, 2023
A growing number of companies in the biotech and healthcare industries are using AI to revolutionize drug discovery and patient care, leading to stock surges.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia is the Sniper of the AI Drug Discovery Industry
July 27, 2023
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia Initiates Prospective Observational Study in Ovarian Cancer
July 18, 2023
From
Exscientia
Via
Business Wire
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
July 10, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces Expansion of its Technology Leadership Team
June 29, 2023
From
Exscientia
Via
Business Wire
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Business Update for First Quarter 2023
May 24, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
May 22, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
May 17, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
May 03, 2023
From
Exscientia plc
Via
Business Wire
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
April 19, 2023
From
Exscientia plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.